Accession Therapeutics
Developing novel immuno-oncology therapeutics – combining high specificity and potency to counter tumour diversity.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | £25.0m | Late VC |
| Total Funding | 000k | ||
Related Content
Accession Therapeutics is a biotechnology startup that operates in the field of immuno-oncology. The company is focused on developing innovative treatments for some of the most challenging and widespread forms of cancer. The business model revolves around the development and commercialization of its proprietary stealth virus platform technology, Trocept, which is designed to target and eradicate all cells in a tumor, regardless of diversity. This technology offers a significant advancement in cancer treatment by eliminating many of the drawbacks of current immunotherapies.
The company is led by immuno-oncology pioneer Bent Jakobsen, PhD FMedSci, who is driving the development of a pipeline of highly differentiated products. Accession Therapeutics' first drug candidate is currently at the IND-enabling stage, which means it is being prepared for clinical trials, with these trials planned for 2024. The company plans to follow this with a pipeline of candidates engineered to revolutionize cancer treatment.
Accession Therapeutics' business model is based on the development and eventual commercialization of these innovative cancer treatments. The company's primary clients will be healthcare providers and patients suffering from the types of cancer that its treatments are designed to combat. The company operates in the biotechnology and healthcare markets, which are characterized by high growth potential and significant investment in research and development.
In summary, Accession Therapeutics is a pioneering biotech startup, developing cutting-edge immuno-oncology treatments with the potential to revolutionize cancer care.
Keywords: Biotechnology, Immuno-Oncology, Cancer Treatment, Stealth Virus Platform Technology, Trocept, Clinical Trials, Healthcare Providers, Patients, Research and Development, Commercialization.